QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad
Genetics (NASDAQ: MYGN) today announced a new master collaboration
agreement to develop companion diagnostic tests in the field of
cancer.
The partnership aims to deliver innovative
services and products to pharmaceutical companies, enabling the
development and commercialization of proprietary cancer tests for
the U.S. clinical market, and providing distributable companion
diagnostic test kits for the global market.
The alliance between QIAGEN and Myriad brings
together the respective strengths of each partner. Myriad leverages
its CLIA-certified, CAP-accredited lab platform, assay development
expertise and robust commercial infrastructure for clinical sample
testing. QIAGEN will provide Sample to Insight solutions, including
sample preparation, its PCR, digital PCR (using the QIAcuity
system), QIAseq next-generation sequencing (NGS) technologies,
instruments, as well as the QIAGEN Digital Insights portfolio of
bioinformatics. Additionally, QIAGEN contributes GMP-certified
product manufacturing capabilities and globally established
commercial channels. The partnership also capitalizes on the
combined FDA and worldwide regulatory expertise of both companies,
providing seamless compliance and integration in clinical and
companion diagnostic applications.
“We are pleased to collaborate with Myriad,
combining their expertise in complex and proprietary lab-developed
tests with our proficiency in distributable kit-based solutions, to
offer a comprehensive global companion diagnostic approach. Our
partnership aims to accelerate the advancement of cancer companion
diagnostics, making them accessible to pharma partners worldwide,”
said Jonathan Arnold, Vice President, Head of Translational Science
and Precision Diagnostics at QIAGEN. “Together, we share the common
goal of improving patient care and guiding treatment decisions in
oncology through our combined expertise and capabilities.”
Our partnership with QIAGEN creates a
comprehensive companion diagnostic development and
commercialization solution for our pharma partners that will
support the advancement of cancer care and personalized treatment
decisions for patients worldwide,” said Paul Bartel, Senior Vice
President of Companion Diagnostics, Myriad Genetics. “As we grow
Myriad’s presence globally in the companion diagnostics space, we
are excited to partner with QIAGEN to increase access to these
solutions, and help more patients and providers make effective
therapeutic choices.”
The initial project focus for the two companies
will involve collaborating with pharma partners to develop assays
utilizing next-generation sequencing workflows or QIAGEN’s digital
PCR platform, QIAcuity.
Future projects are under consideration to
explore advancing and kitting next-generation detection of
measurable residual disease (MRD), which involves using circulating
tumor DNA (ctDNA) assays to detect cancer that may remain in a
patient’s body following treatment, and homologous recombination
deficiency (HRD), a condition where cells are unable to repair
damaged DNA effectively, potentially increasing the survival
ability for cancers treated with chemotherapy.
MRD is a highly complex workflow, and both
companies plan to collaborate in assessing the feasibility of
integrating digital PCR to produce a kitted and standardized
solution for diagnostic laboratories.
QIAGEN has master collaboration agreements to
develop and commercialize companion diagnostics with more than 30
global pharma and biotech companies – a deep pipeline that
will advance precision medicines in diverse disease indications,
tailoring a patient’s treatment to the genetic profile identified
by companion diagnostics testing. Myriad has provided testing
support for hundreds of clinical trials, has obtained 10 companion
diagnostic approvals from the FDA and PMDA, and anticipates that
the QIAGEN partnership will drive the expansion of the Myriad
portfolio of oncology products.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision
medicine company dedicated to advancing health and well-being for
all. Myriad develops and offers genetic tests that help assess the
risk of developing disease or disease progression and guide
treatment decisions across medical specialties where genetic
insights can significantly improve patient care and lower
healthcare costs. For more information, visit www.myriad.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
June 30, 2023, QIAGEN employed more than 6,100 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release constitute forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended, including statements relating to QIAGEN’s and
Myriad’s partnership to develop companion diagnostic tests and
solutions, expected future projects, and the anticipated benefits
of the companies’ partnership. To the extent that any of the
statements contained herein relating to QIAGEN's products,
including those products used in the response to the COVID-19
pandemic, timing for launch and development, marketing and/or
regulatory approvals, financial and operational outlook, growth and
expansion, collaborations, markets, strategy or operating results,
including without limitation its expected adjusted net sales and
adjusted diluted earnings results, are forward-looking, such
statements are based on current expectations and assumptions that
involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with
management of growth and international operations (including the
effects of currency fluctuations, regulatory processes and
dependence on logistics), variability of operating results and
allocations between customer classes, the commercial development of
markets for our products to customers in academia, pharma, applied
testing and molecular diagnostics; changing relationships with
customers, suppliers and strategic partners; competition; rapid or
unexpected changes in technologies; fluctuations in demand for
QIAGEN's products (including fluctuations due to general economic
conditions, the level and timing of customers' funding, budgets and
other factors); our ability to obtain regulatory approval of our
products; difficulties in successfully adapting QIAGEN's products
to integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Any “forward-looking statements” relating to
Myriad are Myriad's management’s expectations of future events as
of the date hereof and are subject to known and unknown risks and
uncertainties that could cause actual results, conditions, and
events to differ materially and adversely from those anticipated.
Such factors include those risks described in Myriad’s filings with
the U.S. Securities and Exchange Commission, including Myriad’s
Annual Report on Form 10-K filed on March 1, 2023, as well as any
updates to those risk factors filed from time to time Myriad’s
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Myriad is not under any obligation, and it expressly disclaims any
obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
pr@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
Matt Scalo
Myriad Genetics
+1 (801) 584-3532
IR@myriad.com
Glenn Farrell
Myriad Genetics
+1 (385) 318-3718
PR@myriad.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024